Amylyx Pharmaceuticals, Inc. (AMLX) Analyst Ratings
AMLX Analyst Consensus & Price Target
Amylyx Pharmaceuticals, Inc. (AMLX) carries a consensus rating of Strong Buy from 9 analysts on record (Mar 11, 2024 to Aug 19, 2026): 9 bullish, 0 neutral, 0 bearish. The average price target is $22.25 (range $10.00 to $55.00), with wide disagreement among analysts. That implies +36.0% downside from the current price of $34.74. Recent activity leans toward upgrades: 3 upgrades vs 2 downgrades on record. The price target on record has moved from $4.00 to $42.00 (+950.0%) between Mar 11, 2024 and Aug 19, 2026.
One vote per analyst, using each firm's most recent rating on record, not every historical reiteration counted separately.
Each analyst's most recent target on record, compared against where the stock actually trades. See how actual results have compared to estimates →
Is the average price target keeping pace with the stock, running ahead of it, or lagging behind? Compares the target's overall drift on record (across different analysts) to the stock's own move over the same window.
Price targets have risen faster than the stock itself.
Every rating on record, most recent first. "Next-close move" is the stock's own move from the prior close to the rating date's close, where price history lines up, a data point per event, not an averaged claim.
| Date | Analyst | Action | Rating | Price Target | Move |
|---|---|---|---|---|---|
| Aug 19, 2026 | Mizuho | Reiterated | Outperform | $30 to $42 | +80.12% |
| Aug 18, 2026 | HC Wainwright & Co. | Reiterated | Buy | $34 to $55 | — |
| Mar 3, 2026 | Stifel | Initiated | Buy | $21 | -7.78% |
| Jul 10, 2025 | Goldman | Resumed | Buy | $10 | +2.07% |
| Jun 24, 2025 | Guggenheim | Initiated | Buy | $17 | +27.69% |
| Jun 17, 2025 | Citigroup | Initiated | Buy | $12 | -2.02% |
| May 30, 2025 | TD Cowen | Initiated | Buy | — | +5.10% |
| Apr 7, 2025 | Mizuho | Upgrade | Neutral to Outperform | $7 | +0.87% |
| Nov 18, 2024 | Robert W. Baird | Upgrade | Neutral to Outperform | $3 to $11 | +11.34% |
| Oct 23, 2024 | BofA Securities | Upgrade | Neutral to Buy | $4.20 to $10 | +9.49% |
| Mar 18, 2024 | Mizuho | Downgrade | Buy to Neutral | $32 to $4 | -11.73% |
| Mar 11, 2024 | Robert W. Baird | Downgrade | Outperform to Neutral | $37 to $4 | +13.10% |
What is the analyst consensus rating for AMLX?
Amylyx Pharmaceuticals, Inc.'s consensus rating is Strong Buy, based on 9 analysts' most recent ratings on record: 9 bullish, 0 neutral, 0 bearish.
What is AMLX's average analyst price target?
The average price target on record is $22.25, ranging from $10.00 to $55.00 across 8 analysts, wide disagreement. That implies -36.0% from the current price of $34.74.
Are analysts upgrading or downgrading AMLX right now?
On record between Mar 11, 2024 and Aug 19, 2026: 3 upgrades, 2 downgrades, 4 new initiations, and 2 reiterations.
Are analyst price targets for AMLX rising or falling?
The price target on record moved from $4.00 on Mar 11, 2024 to $42.00 on Aug 19, 2026, a change of +950.0%. This compares different analysts over time, not one analyst's revision.
How many analysts cover AMLX?
9 analysts have rated AMLX in the data on record, spanning Mar 11, 2024 to Aug 19, 2026.